JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$5.47B |
| 2 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$3.17B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$2.05B |
| 4 |
Amazon
AMZN
|
+$1.96B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.6B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$1.72B |
| 2 |
Vanguard Intermediate-Term Treasury ETF
VGIT
|
+$1.31B |
| 3 |
UnitedHealth
UNH
|
+$1.26B |
| 4 |
Automatic Data Processing
ADP
|
+$1.17B |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$1.08B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.28% |
| 2 | Technology | 17.17% |
| 3 | Healthcare | 10.79% |
| 4 | Financials | 9.36% |
| 5 | Consumer Discretionary | 8.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3326
Vanguard Emerging Markets Government Bond ETF
VWOB
$6.12B
| $2.2M | ﹤0.01% |
35,372
-6,438
| -15% | -$400K |
2015 Q4
29 quarters
|
|
|
NGM
3327
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $2.2M | ﹤0.01% |
539,862
-26,677
| -5% | -$123K |
2019 Q2
15 quarters
|
|
3328
FIGS
FIGS
$2.34B
| $2.19M | ﹤0.01% |
354,503
+223,740
| +171% | +$1.72M |
2021 Q2
7 quarters
|
|
3329
Allegiant Air
ALGT
$2.12B
| $2.19M | ﹤0.01% |
23,767
+7,019
| +42% | +$631K |
2015 Q1
32 quarters
|
|
3330
The GEO Group
GEO
$3.94B
| $2.18M | ﹤0.01% |
276,577
-31,780
| -10% | -$312K |
2014 Q3
34 quarters
|
|
|
KRTX
3331
PUT
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $2.18M | ﹤0.01% |
+12,000
| New | +$2.3M |
2023 Q1
0 quarters
|
|
3332
Varex Imaging
VREX
$785M
| $2.18M | ﹤0.01% |
119,688
-92,844
| -44% | -$1.77M |
2017 Q1
24 quarters
|
|
3333
CALL
Vertex Pharmaceuticals
VRTX
$127B
| $2.17M | ﹤0.01% |
6,900
-48,200
| -87% | -$14.5M |
2021 Q1
8 quarters
|
|
3334
PUT
PNC Financial Services
PNC
$87.8B
| $2.17M | ﹤0.01% |
17,100
-22,600
| -57% | -$3.41M |
2021 Q2
7 quarters
|
|
|
HES
3335
PUT
DELISTED
Hess
HES
| $2.17M | ﹤0.01% |
16,400
-5,000
| -23% | -$696K |
2022 Q2
3 quarters
|
|
3336
Adecoagro
AGRO
$1.56B
| $2.17M | ﹤0.01% |
267,884
+133,447
| +99% | +$1.07M |
2020 Q2
11 quarters
|
|
3337
Matthews International
MATW
$606M
| $2.16M | ﹤0.01% |
59,955
+7,152
| +14% | +$263K |
2013 Q2
39 quarters
|
|
3338
Ryan Specialty Holdings
RYAN
$4.68B
| $2.15M | ﹤0.01% |
53,438
+7,470
| +16% | +$307K |
2021 Q3
6 quarters
|
|
3339
The Joint Corp
JYNT
$101M
| $2.15M | ﹤0.01% |
127,471
-1,249
| -1% | -$20.7K |
2019 Q1
16 quarters
|
|
|
ACB
3340
Aurora Cannabis
ACB
$291M
| $2.14M | ﹤0.01% |
24,800
-17,959
| -42% | -$157K |
2018 Q4
17 quarters
|
|
3341
AMC Entertainment Holdings
AMC
$2.63B
| $2.14M | ﹤0.01% |
42,719
+17,295
| +68% | +$916K |
2015 Q4
29 quarters
|
|
3342
Vanguard S&P Small-Cap 600 ETF
VIOO
$4.08B
| $2.14M | ﹤0.01% |
24,081
+21,253
| +752% | +$1.95M |
2017 Q4
21 quarters
|
|
3343
Globalstar
GSAT
$10.8B
| $2.13M | ﹤0.01% |
122,699
+39,554
| +48% | +$729K |
2020 Q1
12 quarters
|
|
3344
CALL
Innoviz Technologies
INVZ
$97.7M
| $2.13M | ﹤0.01% |
610,000
+100,000
| +20% | +$443K |
2022 Q4
1 quarter
|
|
3345
Tootsie Roll Industries
TR
$2.81B
| $2.13M | ﹤0.01% |
51,842
+9,588
| +23% | +$382K |
2013 Q2
39 quarters
|
|
3346
Scholastic
SCHL
$681M
| $2.12M | ﹤0.01% |
62,018
+13,732
| +28% | +$585K |
2015 Q3
30 quarters
|
|
3347
CALL
Bilibili
BILI
$6.14B
| $2.12M | ﹤0.01% |
+90,000
| New | +$2.14M |
2023 Q1
0 quarters
|
|
|
JNCE
3348
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $2.1M | ﹤0.01% |
1,136,847
+886,639
| +354% | +$1.1M |
2017 Q1
24 quarters
|
|
3349
Tecnoglass Holdings
TGLS
$1.63B
| $2.1M | ﹤0.01% |
50,094
+514
| +1% | +$18.4K |
2021 Q3
6 quarters
|
|
3350
CareDx
CDNA
$3.3B
| $2.09M | ﹤0.01% |
229,152
-113,031
| -33% | -$1.45M |
2017 Q4
21 quarters
|
|
Similar funds
JP Morgan Chase's Q1 2023 Portfolio in Review
As of Q1 2023, JP Morgan Chase held 7,579 positions worth $821B, up 8.2% from $759B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
JP Morgan Chase's Q1 2023 filing shows 751 new, 3,314 increased, 2,056 reduced and 652 closed positions. Its largest new stake was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M. The largest sale was Eli Lilly, an estimated $1.72B.
By sector, the portfolio is most concentrated in Miscellaneous at 27% of assets, up from 27% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q1 2023 buy was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M.
- JP Morgan Chase added most to JPMorgan BetaBuilders Europe ETF in Q1 2023, an estimated $5.47B increase.
- JP Morgan Chase's biggest Q1 2023 reduction was Eli Lilly, cutting an estimated $1.72B.
- JP Morgan Chase fully exited IAA, Inc. Common Stock in Q1 2023, selling an estimated $155M.
- JP Morgan Chase's ten largest holdings make up 17% of its $821B portfolio in Q1 2023.
- JP Morgan Chase opened 751 new positions and closed 652 in Q1 2023.
- JP Morgan Chase's portfolio value rose 8.2% quarter-over-quarter to $821B.
Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.